Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study

Loredana Miglietta, Luciano Canobbio, Cristina Granetto, Maria Ornella Vannozzi, Mauro Esposito, Francesco Boccardo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Previous studies indicate that suramin may be an active agent for treating hormone-refractory prostate cancer. However, antitumour responses were observed in initial experiments only when plasma suramin concentrations were maintained in excess of 250 μg/ml. Dose-limiting toxicity, especially neurological toxicity, is directly related to the duration of exposure and sustained plasma drug concentrations of 300 μg/ml or more. Combination with other agents such as epidoxorubicin, a drug with demonstrable activity in metastatic prostatic carcinoma, could be more effective and allow reduced suramin doses, while maintaining the suramin antitumor effect; this could make suramin therapy more feasible. On the basis of preclinical synergistic activity for combined suramin/doxorubicin in prostate cancer cell lines, a pilot study in patients with metastatic hormone refractory prostate cancer was performed. Materials and methods: Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2. Therapy was discontinued for dose-limiting toxicity or progressive disease. Results: None of the ten patients achieved a prostate-specific antigen reduction of more than 50% and no objective responses were observed in any patient. Dose-limiting toxicity was observed in four patients: grade 3 neurotoxicity was observed in three patients and grade 3 nephrotoxicity in one patient. Conclusions: Suramin/epidoxorubicin association, despite the encouraging preclinical results, was not able to improve the antitumour activity of suramin and showed significant toxicity. The results achieved in our study, although in a small number of patients, seem to suggest that this regimen cannot be recommended for use in the treatment of metastatic hormone- refractory prostate cancer.

Original languageEnglish
Pages (from-to)407-410
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Volume123
Issue number7
DOIs
Publication statusPublished - 1997

Fingerprint

Suramin
Prostatic Neoplasms
Hormones
Prostate-Specific Antigen
Pharmaceutical Preparations
Doxorubicin
Therapeutics
Carcinoma
Cell Line

Keywords

  • Epidoxorubicin
  • Hormone-refractory
  • Prostate Cancer
  • Suramin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Suramin/epidoxorubicin association in hormone-refractory prostate cancer : Preliminary results of a pilot phase II study. / Miglietta, Loredana; Canobbio, Luciano; Granetto, Cristina; Vannozzi, Maria Ornella; Esposito, Mauro; Boccardo, Francesco.

In: Journal of Cancer Research and Clinical Oncology, Vol. 123, No. 7, 1997, p. 407-410.

Research output: Contribution to journalArticle

Miglietta, Loredana ; Canobbio, Luciano ; Granetto, Cristina ; Vannozzi, Maria Ornella ; Esposito, Mauro ; Boccardo, Francesco. / Suramin/epidoxorubicin association in hormone-refractory prostate cancer : Preliminary results of a pilot phase II study. In: Journal of Cancer Research and Clinical Oncology. 1997 ; Vol. 123, No. 7. pp. 407-410.
@article{c7c1496086a24046bf05d5fd2d580f69,
title = "Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study",
abstract = "Purpose: Previous studies indicate that suramin may be an active agent for treating hormone-refractory prostate cancer. However, antitumour responses were observed in initial experiments only when plasma suramin concentrations were maintained in excess of 250 μg/ml. Dose-limiting toxicity, especially neurological toxicity, is directly related to the duration of exposure and sustained plasma drug concentrations of 300 μg/ml or more. Combination with other agents such as epidoxorubicin, a drug with demonstrable activity in metastatic prostatic carcinoma, could be more effective and allow reduced suramin doses, while maintaining the suramin antitumor effect; this could make suramin therapy more feasible. On the basis of preclinical synergistic activity for combined suramin/doxorubicin in prostate cancer cell lines, a pilot study in patients with metastatic hormone refractory prostate cancer was performed. Materials and methods: Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2. Therapy was discontinued for dose-limiting toxicity or progressive disease. Results: None of the ten patients achieved a prostate-specific antigen reduction of more than 50{\%} and no objective responses were observed in any patient. Dose-limiting toxicity was observed in four patients: grade 3 neurotoxicity was observed in three patients and grade 3 nephrotoxicity in one patient. Conclusions: Suramin/epidoxorubicin association, despite the encouraging preclinical results, was not able to improve the antitumour activity of suramin and showed significant toxicity. The results achieved in our study, although in a small number of patients, seem to suggest that this regimen cannot be recommended for use in the treatment of metastatic hormone- refractory prostate cancer.",
keywords = "Epidoxorubicin, Hormone-refractory, Prostate Cancer, Suramin",
author = "Loredana Miglietta and Luciano Canobbio and Cristina Granetto and Vannozzi, {Maria Ornella} and Mauro Esposito and Francesco Boccardo",
year = "1997",
doi = "10.1007/s004320050079",
language = "English",
volume = "123",
pages = "407--410",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Suramin/epidoxorubicin association in hormone-refractory prostate cancer

T2 - Preliminary results of a pilot phase II study

AU - Miglietta, Loredana

AU - Canobbio, Luciano

AU - Granetto, Cristina

AU - Vannozzi, Maria Ornella

AU - Esposito, Mauro

AU - Boccardo, Francesco

PY - 1997

Y1 - 1997

N2 - Purpose: Previous studies indicate that suramin may be an active agent for treating hormone-refractory prostate cancer. However, antitumour responses were observed in initial experiments only when plasma suramin concentrations were maintained in excess of 250 μg/ml. Dose-limiting toxicity, especially neurological toxicity, is directly related to the duration of exposure and sustained plasma drug concentrations of 300 μg/ml or more. Combination with other agents such as epidoxorubicin, a drug with demonstrable activity in metastatic prostatic carcinoma, could be more effective and allow reduced suramin doses, while maintaining the suramin antitumor effect; this could make suramin therapy more feasible. On the basis of preclinical synergistic activity for combined suramin/doxorubicin in prostate cancer cell lines, a pilot study in patients with metastatic hormone refractory prostate cancer was performed. Materials and methods: Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2. Therapy was discontinued for dose-limiting toxicity or progressive disease. Results: None of the ten patients achieved a prostate-specific antigen reduction of more than 50% and no objective responses were observed in any patient. Dose-limiting toxicity was observed in four patients: grade 3 neurotoxicity was observed in three patients and grade 3 nephrotoxicity in one patient. Conclusions: Suramin/epidoxorubicin association, despite the encouraging preclinical results, was not able to improve the antitumour activity of suramin and showed significant toxicity. The results achieved in our study, although in a small number of patients, seem to suggest that this regimen cannot be recommended for use in the treatment of metastatic hormone- refractory prostate cancer.

AB - Purpose: Previous studies indicate that suramin may be an active agent for treating hormone-refractory prostate cancer. However, antitumour responses were observed in initial experiments only when plasma suramin concentrations were maintained in excess of 250 μg/ml. Dose-limiting toxicity, especially neurological toxicity, is directly related to the duration of exposure and sustained plasma drug concentrations of 300 μg/ml or more. Combination with other agents such as epidoxorubicin, a drug with demonstrable activity in metastatic prostatic carcinoma, could be more effective and allow reduced suramin doses, while maintaining the suramin antitumor effect; this could make suramin therapy more feasible. On the basis of preclinical synergistic activity for combined suramin/doxorubicin in prostate cancer cell lines, a pilot study in patients with metastatic hormone refractory prostate cancer was performed. Materials and methods: Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2. Therapy was discontinued for dose-limiting toxicity or progressive disease. Results: None of the ten patients achieved a prostate-specific antigen reduction of more than 50% and no objective responses were observed in any patient. Dose-limiting toxicity was observed in four patients: grade 3 neurotoxicity was observed in three patients and grade 3 nephrotoxicity in one patient. Conclusions: Suramin/epidoxorubicin association, despite the encouraging preclinical results, was not able to improve the antitumour activity of suramin and showed significant toxicity. The results achieved in our study, although in a small number of patients, seem to suggest that this regimen cannot be recommended for use in the treatment of metastatic hormone- refractory prostate cancer.

KW - Epidoxorubicin

KW - Hormone-refractory

KW - Prostate Cancer

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0030763677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030763677&partnerID=8YFLogxK

U2 - 10.1007/s004320050079

DO - 10.1007/s004320050079

M3 - Article

C2 - 9260594

AN - SCOPUS:0030763677

VL - 123

SP - 407

EP - 410

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -